Table 1

Distribution of genotypes of the CYP17 5′UTR polymorphism in breast cancer patients and healthy controls. Relationship to stage of the disease and age of the patients at diagnosis.

GenotypeBreast cancer patients (n = 510)Controls (n = 201)Age at diagnosis, yearsStage of diseaseAge + stage
<45 (n = 75)>55 (n = 257)I+II (n = 272)III+IV (n = 142)<45 and I+II (n = 54)>55 and III+IV (n = 93)
A1A1 202 (39.6%)74 (36.8%)27 (36.0%)99 (38.5%)108 (39.7%)56 (39.4%)19 (35.2%)35 (37.6%)
A1A2 241 (47.3%)101 (50.3%)42 (56.0%)119 (46.3%)129 (47.4%)66 (46.5%)30 (55.6%)41 (44.1%)
A2A2 67 (13.1%)26 (12.9%)6 (8.0%)39 (15.2%)35 (12.9%)20 (20%)5 (9.2%)17 (18.3%)
P = 0.76P = 0.16P= 0.94P = 0.23